<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preterm prelabor rupture of membranes: Management and outcome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preterm prelabor rupture of membranes: Management and outcome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Preterm prelabor rupture of membranes: Management and outcome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Duff, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1683472693"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prelabor rupture of membranes (PROM) refers to membrane rupture before the onset of uterine contractions. Preterm PROM (PPROM) refers to PROM before 37+0 weeks of gestation. It is responsible for, or associated with, approximately one-third of preterm births and is the single most common identifiable factor associated with preterm delivery.</p><p>The management of PPROM is among the most controversial issues in perinatal medicine. Points of contention include:</p><p class="bulletIndent1"><span class="glyph">●</span>Accurate diagnosis in problematic cases</p><p class="bulletIndent1"><span class="glyph">●</span>Expectant management versus intervention</p><p class="bulletIndent1"><span class="glyph">●</span>Use of tocolytics</p><p class="bulletIndent1"><span class="glyph">●</span>Duration of administration of antibiotic prophylaxis</p><p class="bulletIndent1"><span class="glyph">●</span>Timing of administration of antenatal corticosteroids</p><p class="bulletIndent1"><span class="glyph">●</span>Methods of testing for maternal/fetal infection</p><p class="bulletIndent1"><span class="glyph">●</span>Timing of delivery</p><p></p><p>Management and outcome of PPROM from 23+0 to 36+6 weeks of gestation will be discussed here. Issues specifically relating to management of PPROM before the limit of viability and term PROM are reviewed separately. (See  <a class="medical medical_review" href="/d/html/6741.html" rel="external">"Prelabor rupture of membranes before and at the limit of viability"</a> and  <a class="medical medical_review" href="/d/html/6757.html" rel="external">"Prelabor rupture of membranes at term: Management"</a>.)</p><p>The epidemiology, pathogenesis, clinical manifestations, diagnosis, and clinical course of PPROM from 23+0 to 36+6 weeks of gestation are also reviewed separately. (See  <a class="medical medical_review" href="/d/html/6754.html" rel="external">"Preterm prelabor rupture of membranes: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H3825056879"><span class="h1">ANTEPARTUM MANAGEMENT</span></p><p class="headingAnchor" id="H1514188812"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The management of pregnancies complicated by PPROM is based upon consideration of several factors, which are assessed upon presentation:</p><p class="bulletIndent1"><span class="glyph">●</span>Gestational age</p><p class="bulletIndent1"><span class="glyph">●</span>Presence or absence of maternal/fetal infection</p><p class="bulletIndent1"><span class="glyph">●</span>Presence or absence of labor</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal presentation</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal well-being</p><p class="bulletIndent1"><span class="glyph">●</span>Expectation of fetal lung maturity based on gestational age</p><p class="bulletIndent1"><span class="glyph">●</span>Cervical status (by visual inspection)</p><p class="bulletIndent1"><span class="glyph">●</span>Availability of an appropriate level of neonatal care</p><p></p><p>Some tests that can be useful in this assessment are listed in the table  (<a class="graphic graphic_table graphicRef88806" href="/d/graphic/88806.html" rel="external">table 1</a>). Screening for infection by standard methods is useful for guiding antibiotic therapy, but vaginal culture is not helpful since the vaginal flora is normally polymicrobial. (See <a class="local">'Screen for infection'</a> below and <a class="local">'Administer prophylactic antibiotic therapy'</a> below.)</p><p>The key decision is whether to induce labor (or perform cesarean delivery) or to manage the pregnancy expectantly. The early preterm fetus (ie, &lt;34+0 weeks) who is otherwise stable will benefit by prolonging the time it remains in the uterus if the duration is sufficient to allow a significant reduction in gestational age-related morbidity [<a href="#rid1">1-3</a>]. The late preterm fetus (34+0 to 36+6 weeks) may benefit as well, although there is less consensus at this gestational age. However, this benefit needs to be balanced with the risks of PPROM-associated complications and their sequelae in expectantly managed pregnancies: intrauterine infection, placental abruption, and cord prolapse/compression.</p><p>Expeditious delivery of women with PPROM is appropriate in the setting of intrauterine infection, placental abruption, or nonreassuring fetal testing [<a href="#rid4">4</a>]. In each of these conditions, fetal well-being can deteriorate rapidly with expectant management, and there are no therapeutic interventions available other than delivery. For the same reason, an unstable lie with a high risk of cord prolapse is an indication for delivery rather than expectant management, but the balance between the risks of cord prolapse and birth of a very or extremely preterm birth also needs to be considered on a case-by-case basis. (See  <a class="medical medical_review" href="/d/html/6826.html" rel="external">"Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences"</a> and  <a class="medical medical_review" href="/d/html/6762.html" rel="external">"Clinical chorioamnionitis"</a> and  <a class="medical medical_review" href="/d/html/4461.html" rel="external">"Umbilical cord prolapse"</a>.)</p><p>In the absence of complications, there is a consensus that patients with PPROM before 34+0 weeks should be monitored closely and managed expectantly at least until 34+0 weeks of gestation. We believe that well-dated pregnancies initially managed expectantly should be delivered at 34+0 weeks of gestation, but continuing expectant management until 37 weeks is also a reasonable approach. A more detailed discussion of delivery timing is provided below. (See <a class="local">'Timing of delivery'</a> below.)</p><p class="headingAnchor" id="H2901548616"><span class="h2">Components of expectant management</span></p><p class="headingAnchor" id="H3974313118"><span class="h3">Administer antenatal corticosteroids</span><span class="headingEndMark"> — </span>A course of corticosteroids should be administered to pregnancies that present with PPROM between 23+0 and 33+6 weeks of gestation. Data supporting this recommendation were provided by meta-analyses of randomized trials that showed significant reductions in neonatal death, respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, and duration of neonatal respiratory support after antenatal corticosteroid treatment in pregnancies at risk for preterm birth, without an increase in either maternal or neonatal infection [<a href="#rid5">5,6</a>]. Mean risk reduction for these adverse events ranged from 30 to 60 percent. </p><p>A course of corticosteroids can be considered for patients who present with PPROM at 34+0 to 36+6 weeks of gestation who are going to be managed expectantly, have not received a previous course of steroids, and who are scheduled for delivery in &gt;24 hours and &lt;7 days [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery", section on 'Candidates for a first ACS course by gestational age'</a>.)</p><p>Administration of antenatal steroids for pregnancies that present with PPROM in the 22nd week of gestation is also reasonable if delivery in the next seven days is anticipated and the family desires aggressive neonatal intervention after thorough consultation with maternal-fetal medicine and neonatology specialists. Data regarding outcomes of these pregnancies are reviewed separately. (See  <a class="medical medical_review" href="/d/html/6741.html" rel="external">"Prelabor rupture of membranes before and at the limit of viability", section on 'Pediatric outcomes'</a> and  <a class="medical medical_review" href="/d/html/13511.html" rel="external">"Periviable birth (limit of viability)"</a> and  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery", section on '22+0 to 22+6 weeks'</a> and  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery", section on '23+0 to 33+6 weeks'</a>.)</p><p>The author also administers a single rescue course of <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a> to pregnancies up to 34 weeks of gestation that meet standard criteria: high risk of delivery within 7 days and prior exposure to antenatal corticosteroids more than 14 days earlier [<a href="#rid8">8</a>]. Analysis of trials including but not limited to pregnancies with PPROM demonstrated that a repeat course of betamethasone produced short-term benefits compared with a single course and no long-term adverse effects in children followed up to eight years of age [<a href="#rid9">9</a>]. However, multiple courses (ie, more than a single rescue course) should be avoided as they do not provide significant added benefit and can be harmful. </p><p>The effect of PPROM on fetal pulmonary maturation is unclear as studies have reported inconsistent results. This discordancy may be due to failure to adjust for factors that affect neonatal respiratory function, such as mode of delivery and presence or absence of labor, as well as gestational age, duration of latency, and comorbidities such as chorioamnionitis [<a href="#rid10">10</a>]. Fetal exposure to inflammation can induce interleukin (IL)-1 production, which enhances surfactant protein and lipid synthesis thereby promoting lung maturation; however, adverse effects on lung development and outcome can also occur [<a href="#rid11">11-13</a>]. Some UpToDate authors do not administer rescue steroids to patients with PPROM because a benefit in this setting has not been demonstrated [<a href="#rid14">14</a>].</p><p>Regimens for rescue steroids, benefits and potential harms of antenatal corticosteroids, and guidelines for use are available separately. (See  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery", section on 'Use of rescue (salvage, booster) ACS'</a> and  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery", section on '34+0 or more weeks'</a>.)</p><p class="headingAnchor" id="H3747197364"><span class="h3">Screen for infection</span><span class="headingEndMark"> — </span>The Centers for Disease Control and Prevention (CDC) recommends screening for STIs (eg, HIV, syphilis, chlamydia, gonorrhea) in the third trimester in women with risk factors for acquiring an STI  (<a class="graphic graphic_table graphicRef112388" href="/d/graphic/112388.html" rel="external">table 2</a>) [<a href="#rid15">15</a>].</p><p>In women with PPROM, we perform this screening, as well as screening for group B <em>Streptococcus</em> (GBS), on admission since these pregnancies are at high risk of preterm delivery. Women with positive results are treated as appropriate. In some cases, the prophylactic antibiotic therapy administered to prolong latency will provide adequate treatment.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15892.html" rel="external">"Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents", section on 'Pregnant women'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7579.html" rel="external">"Treatment of <i>Chlamydia trachomatis</i> infection", section on 'Pregnant individuals'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/83476.html" rel="external">"Hepatitis B and pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3637.html" rel="external">"Vertical transmission of hepatitis C virus"</a>.)</p><p></p><p>The author also screens women with PPROM for bacterial vaginosis (BV) and <em>Trichomonas vaginalis</em>; however, screening for these infections is controversial. Testing for BV using Amsel criteria (which includes pH) is problematic since amniotic fluid in the vagina will interfere with pH-based diagnosis of these entities; a positive Gram stain is predictive of BV but has low sensitivity [<a href="#rid16">16</a>]. A commercial test using nucleic acid amplification testing (NAAT; eg, Affirm VPIII or OSOM BVBlue) is the most sensitive option for diagnosis of BV in this setting. (See  <a class="medical medical_review" href="/d/html/5451.html" rel="external">"Bacterial vaginosis: Clinical manifestations and diagnosis", section on 'Clinical laboratory tests'</a>.)</p><p>The author's rationale for screening is that there are potential maternal consequences from these infections, which may be prevented by standard treatment:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5453.html" rel="external">"Trichomoniasis: Clinical manifestations and diagnosis", section on 'Diagnostic evaluation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5451.html" rel="external">"Bacterial vaginosis: Clinical manifestations and diagnosis", section on 'Clinical consequences of BV'</a> and  <a class="medical medical_review" href="/d/html/113103.html" rel="external">"Bacterial vaginosis: Initial treatment", section on 'Pregnant or lactating persons'</a>.)</p><p></p><p>The author does not screen for <em>Mycoplasma </em>species because the <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> in the prophylactic antibiotic regimen to prolong latency covers these organisms, so there is no need to specifically test for them. Furthermore, most hospital microbiology laboratories are not prepared to culture these organisms, and NAATs are not available in most hospital diagnostic laboratories (in the United States, there are no approved nucleic acid-based assays for these organisms). (See  <a class="medical medical_review" href="/d/html/5508.html" rel="external">"<i>Mycoplasma hominis</i> and <i>Ureaplasma </i>infections", section on 'Microbiologic confirmation'</a>.)</p><p class="headingAnchor" id="H923694323"><span class="h4">GBS</span><span class="headingEndMark"> — </span>Chemoprophylaxis specifically for GBS is indicated if GBS test results are positive or unknown and delivery is imminent. Guidelines for diagnosis of maternal GBS colonization and chemoprophylaxis are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/438.html" rel="external">"Prevention of early-onset group B streptococcal disease in neonates", section on 'Special populations'</a>.)</p><p>For patients being managed expectantly, the intravenous portion of the prophylactic antibiotic regimen to prolong latency described below (<a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> 2 grams intravenously every 6 hours for 48 hours) should provide adequate prophylaxis for GBS-colonized women. As noted below, this regimen of intravenous ampicillin, followed by oral <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, combined with a single 1 gram dose of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, is usually given for seven days. After completion of this regimen, antibiotics should be discontinued. If the patient's GBS culture is positive, specific prophylaxis for GBS colonization (eg, penicillin) should be resumed when the patient subsequently goes into labor [<a href="#rid17">17</a>]. (See <a class="local">'Administer prophylactic antibiotic therapy'</a> below.) </p><p>Regimens for women with penicillin allergy are described below. (See <a class="local">'Women with penicillin allergy'</a> below.)</p><p class="headingAnchor" id="H4238790708"><span class="h3">Administer prophylactic antibiotic therapy</span></p><p class="headingAnchor" id="H3593489814"><span class="h4">Rationale</span><span class="headingEndMark"> — </span>Infection can be a cause or a consequence of PPROM. The goal of antibiotic therapy is to reduce the frequency of maternal and fetal infection and thereby delay the onset of preterm labor (ie, prolong latency) and the need for indicated preterm delivery. The importance of reducing infection is underscored by studies suggesting a relationship between chorioamnionitis, duration of membrane rupture, and development of cerebral palsy or neurodevelopmental impairment. (See  <a class="medical medical_review" href="/d/html/6762.html" rel="external">"Clinical chorioamnionitis"</a>.)</p><p>A 2013 systematic review of 22 placebo-controlled randomized trials involving over 6800 women evaluated the use of antibiotics following PPROM before 37 weeks of gestation [<a href="#rid18">18</a>]. Compared with placebo/no treatment, antibiotic use was associated with significant reductions in:</p><p class="bulletIndent1"><span class="glyph">●</span>Chorioamnionitis (relative risk [RR] 0.66, 95% CI 0.46-0.96).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants born within 48 hours (RR 0.71, 95% CI 0.58-0.87) and seven days (RR 0.79, 95% CI 0.71-0.89) of randomization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal infection (RR 0.67, 95% CI 0.52-0.85).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of surfactant (RR 0.83, 95% CI 0.72-0.96).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal oxygen therapy (RR 0.88, 95% CI 0.81-0.96).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal cerebral ultrasound scan prior to hospital discharge (RR 0.81, 95% CI 0.68-0.98).</p><p></p><p>Data were insufficient to determine whether any antibiotic regimen (drug, dose, duration) was better than another, but <a class="drug drug_general" data-topicid="8676" href="/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> appeared to be associated with an increased risk of neonatal necrotizing enterocolitis (RR 4.72, 95% CI 1.57-14.23). The validity of this association requires further investigation in large trials, given the wide confidence interval.</p><p>Based on these and other data, the American College of Obstetricians and Gynecologists (ACOG) recommended antibiotic prophylaxis to prolong latency in pregnancies with PPROM &lt;34+0 weeks of gestation but not for expectantly managed PPROM ≥34+0 weeks [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H76871643"><span class="h4">Drug regimen</span><span class="headingEndMark"> — </span>We recommend administering a seven-day course of prophylactic antibiotics to all women with PPROM &lt;34+0 weeks of gestation who are managed expectantly.</p><p>Our preference is:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> 1 gram orally upon admission, <strong>plus</strong></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">Ampicillin</a> 2 grams intravenously every 6 hours for 48 hours, <strong>followed by</strong></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">Amoxicillin</a> 875 mg orally every 12 hours or 500 mg orally every 8 hours for an additional five days</p><p></p><p><a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">Ampicillin</a> and <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> specifically target GBS, many aerobic gram-negative bacilli, and some anaerobes. <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> specifically targets <em>Ureaplasma</em>, which can be an important cause of chorioamnionitis in this setting [<a href="#rid19">19</a>]. Azithromycin also provides coverage of <em>Chlamydia trachomatis</em>, which is an important cause of neonatal conjunctivitis and pneumonitis. In addition, in patients with PPROM with either intraamniotic infection or sterile intraamniotic inflammation, administration of intravenous <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> has been associated with a reduction in the intensity of the intraamniotic inflammatory response [<a href="#rid20">20</a>].</p><p>The optimal regimen for antibiotic prophylaxis in PPROM was unclear in a 2020 network meta-analysis of randomized trials [<a href="#rid21">21</a>]. Our regimen has reasonable activity against the major genital tract pathogens and is similar to that shown to be effective in the National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network trial on antibiotic therapy for reduction of infant morbidity after PPROM (intravenous <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> 2 grams every 6 hours and <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> 250 mg every 6 hours for 48 hours followed by oral <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> 250 mg every 8 hours and erythromycin 333 mg every 8 hours for five days) [<a href="#rid22">22</a>], which is recommended by ACOG [<a href="#rid23">23</a>]. We give <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> in lieu of a multiple-day course of erythromycin because of its ease of administration, improved gastrointestinal tolerance, favorable cost profile, and similar or better efficacy; this substitution is also endorsed by ACOG [<a href="#rid7">7</a>]. In a 2022 meta-analysis of five observational studies comparing azithromycin with erythromycin for prophylaxis in nearly 1300 pregnancies with PPROM, azithromycin was associated with a lower rate of clinical chorioamnionitis (14.5 versus 24.4 percent; OR 0.53 95% CI 0.39-0.71) [<a href="#rid24">24</a>]. Most patients received a single dose of azithromycin versus a multiday erythromycin regimen. For amoxicillin, the author prefers the 875 mg twice daily dose for patient convenience. He uses a higher dose than that used in the NICHD-MFMU trial to reduce rectovaginal GBS colonization, if present, although data regarding efficacy are not available.</p><p>An animal model investigation illustrates the importance of genital mycoplasmas in the pathogenesis of preterm labor and helps to explain why drugs such as <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> and <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> may be valuable both in prolonging the latent period and reducing the frequency of infection and injury in the baby [<a href="#rid25">25</a>]. In this study, 16 chronically instrumented rhesus monkeys underwent intra-amniotic inoculation with <em>Ureaplasma parvum</em>. Uterine contractions began soon after inoculation, at which time six monkeys received no treatment, five received intravenous azithromycin for 10 days, and five received azithromycin plus <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> and <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> for 10 days. Azithromycin significantly prolonged gestation by approximately seven days, significantly decreased the <em>Ureaplasma</em> colony count in the amniotic fluid, decreased the amniotic fluid concentration of proinflammatory mediators, and decreased the magnitude of histologic lung injury. Interestingly, dexamethasone and indomethacin did not further enhance the treatment effect of azithromycin.</p><p>Prophylactic antibiotics may exert selective pressures for emergence of drug-resistant microorganisms. In addition, there is a theoretical concern that clinical infection may be more difficult to recognize or treat in patients who have received prophylactic antibiotics. These problems have not been observed in women with PPROM receiving antibiotic prophylaxis. Long-term adverse effects of antepartum prophylactic antibiotics for PPROM have not been observed in children followed to age seven years [<a href="#rid26">26</a>]. This finding is in contrast to the observation from the same authors that, in patients with spontaneous preterm labor and intact membranes, the rate of cerebral palsy was increased in children exposed to antibiotics in utero [<a href="#rid27">27</a>].</p><p>Ongoing studies to determine the optimal prophylactic antibiotic regimen are needed, given changes in bacterial sensitivities over time [<a href="#rid28">28</a>]. One expanded-spectrum alternative regimen that has been suggested is <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, and <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> [<a href="#rid19">19</a>]. This regimen has been associated with successful eradication of intra-amniotic inflammation/infection in two studies: one in women with PPROM and the other in women with preterm labor with intact membranes [<a href="#rid19">19,29</a>]. Others have reported that antibiotic prophylaxis regimens based on a third-generation cephalosporin are associated with improved newborn survival without severe morbidity when compared with <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, and without an increase in neonatal sepsis related to third-generation cephalosporin-resistant pathogens [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H1825691200"><span class="h4">Women with penicillin allergy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low risk for anaphylaxis</strong> – If the patient's history suggests a low risk for anaphylaxis  (<a class="graphic graphic_algorithm graphicRef100745" href="/d/graphic/100745.html" rel="external">algorithm 1</a>), we suggest (see  <a class="medical medical_review" href="/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> 1 gram orally upon admission, <strong>plus</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">Cefazolin</a> 1 gram intravenously every 8 hours for 48 hours, <strong>followed by</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9231" href="/d/drug information/9231.html" rel="external">Cephalexin</a> 500 mg orally four times daily for five days</p><p></p><p class="bulletIndent2">The cephalosporins provide coverage for both GBS and<em> Escherichia coli</em>, the two major causes of neonatal infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk for anaphylaxis</strong> – If the patient's history suggests a high risk for anaphylaxis  (<a class="graphic graphic_algorithm graphicRef100745" href="/d/graphic/100745.html" rel="external">algorithm 1</a>), we suggest (see  <a class="medical medical_review" href="/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> 1 gram orally upon admission, <strong>plus</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">Clindamycin</a> 900 mg intravenously every 8 hours for 48 hours, <strong>plus</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">Gentamicin</a> 5 mg/kg actual body weight intravenously every 24 hours for two doses, <strong>followed by</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">Clindamycin</a> 300 mg orally every eight hours for five days</p><p></p><p class="bulletIndent2">This regimen is appropriate for patients with a positive GBS culture and laboratory-documented GBS susceptibility to <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk for anaphylaxis and GBS resistant to </strong><a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a><strong> </strong>– If the patient has a history of a severe penicillin allergy and the GBS culture shows resistance to clindamycin or susceptibility results are not available, we suggest:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> 1 gram orally upon admission, <strong>plus</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> 20 mg/kg every 8 hours (maximum single dose 2 grams) for 48 hours, <strong>plus</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">Gentamicin</a> 5 mg/kg actual body weight intravenously every 24 hours for two doses</p><p></p><p class="headingAnchor" id="H3358677791"><span class="h3">Indications for tocolysis</span><span class="headingEndMark"> — </span>The principal indication for tocolysis in the setting of PPROM is to delay delivery for 48 hours to allow administration of a course of corticosteroids. They also may be used to reduce the risk of delivery while a patient is being transported to a facility with a higher level of neonatal care. As a general rule, tocolytics should not be administered for more than 48 hours. They also should not be administered to patients who are in advanced labor (&gt;4 cm dilation) or who have any findings suggestive of subclinical or overt chorioamnionitis. Other potential contraindications to tocolysis include nonreassuring fetal testing (eg, nonreactive nonstress test [NST]), abruptio placentae, and significant risk of cord prolapse (eg, dilated cervix and fetal malpresentation). (See  <a class="medical medical_review" href="/d/html/6742.html" rel="external">"Inhibition of acute preterm labor"</a> and  <a class="medical medical_review" href="/d/html/17178.html" rel="external">"Inter-facility maternal transport", section on 'Preterm prelabor rupture of membranes'</a>.)</p><p>In a 2014 systematic review of randomized trials evaluating pregnancy outcomes of women with PPROM who received or did not receive tocolytic therapy (prophylactic or therapeutic), tocolysis for pregnancies &lt;34 weeks resulted in fewer births within 48 hours (RR 0.59, 95% CI 0.34-1.00; four trials, n = 243 women), but an increase in chorioamnionitis (RR 1.79, 95% CI 1.02-3.14; three trials, n = 168 women) and no significant improvement in perinatal morbidity or mortality [<a href="#rid31">31</a>]. There are several limitations to these data, including the small number and size of the trials and the fact that patients did not consistently receive antenatal corticosteroids to reduce neonatal morbidity or antibiotics to prolong latency, which diverges with current standards of care and may explain the lack of improvement in clinically important outcomes.</p><p class="headingAnchor" id="H653260620"><span class="h3">Hospitalization versus home care</span><span class="headingEndMark"> — </span>Most clinicians hospitalize women with PPROM who have a viable fetus from the time of diagnosis until delivery. The author limits activity to using the restroom and sitting up in a bedside chair as a prudent approach, although the effect of type and degree of activity on the course of PPROM has not been studied. He also administers thromboprophylaxis because of the potential for deep vein thrombosis and pulmonary embolism in sedentary hospitalized patients. The method of thromboprophylaxis may be sequential compression devices and/or <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a>, 40 mg subcutaneously daily for most patients at low to average risk of thrombosis. (See  <a class="medical medical_review" href="/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention", section on 'Administration'</a>.)</p><p>There have been only two randomized trials evaluating the safety of outpatient versus inpatient management of women with PPROM [<a href="#rid32">32,33</a>]. The smaller trial included only 21 women with PPROM as part of a larger study of antenatal day care versus in-hospital care [<a href="#rid33">33</a>]. The larger trial, which included 67 women with PPROM, randomly assigned one group to expectant management at home and the other to expectant management in the hospital [<a href="#rid32">32</a>]. Both groups were managed similarly with bedrest, recording of temperature and pulse every six hours, daily charting of fetal movements, twice-weekly NSTs and complete blood count, and weekly ultrasound and visual examination of the cervix. Only 18 percent of the women met the strict safety criteria used for inclusion  (<a class="graphic graphic_table graphicRef55156" href="/d/graphic/55156.html" rel="external">table 3</a>), and three women managed at home delivered unexpectedly at outside hospitals. A meta-analysis of these trials found no significant differences in maternal or neonatal outcomes between the hospital and home care groups, although the home group had lower maternal costs [<a href="#rid34">34</a>]. However, these small trials did not have sufficient statistical power to detect meaningful differences between groups.</p><p>In a retrospective study of 187 women with PPROM managed as outpatients, 12 had a severe complication (fetal death, placental abruption, umbilical cord prolapse, delivery outside of a maternity hospital, neonatal death) [<a href="#rid35">35</a>]. PPROM occurring before 26 weeks, noncephalic fetal presentation, and oligohydramnios significantly increase the risk for a severe complication, especially when more than one factor is present; therefore, these factors are an indication for hospitalization rather than outpatient management [<a href="#rid35">35,36</a>].</p><p>Further study is needed to determine the safety of outpatient management. In particular, the possibility and risks of a delay in diagnosis of maternal infection, cord prolapse, and precipitous labor and delivery need to be addressed [<a href="#rid32">32,37</a>]. Until we have definitive evidence supporting the safety of outpatient management in carefully selected individuals, we strongly recommend managing all patients in the hospital.</p><p class="headingAnchor" id="H2227571636"><span class="h3">Fetal monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonstress test and biophysical profile</strong> – Some type of fetal surveillance is generally employed (eg, kick counts, NSTs, biophysical profile [BPP]) to provide the clinician and patient some assurance of fetal well-being [<a href="#rid38">38</a>]. At our center, we perform a daily NST. If the NST is not reassuring, we perform a BPP. However, none of these tests have good sensitivity for predicting fetal infection, even when performed daily (sensitivity of daily NST and BPP: 39 and 25 percent, respectively [<a href="#rid39">39</a>]).</p><p></p><p class="bulletIndent1">PPROM does not alter the way the BPP is calculated or interpreted. A low BPP score (0, 2, or 4) should be managed in standard fashion. The predictive value for infection is low since the low score may be due to infection or to oligohydramnios and absent fetal breathing related to PPROM. (See  <a class="medical medical_review" href="/d/html/5392.html" rel="external">"Biophysical profile test for antepartum fetal assessment"</a>.)</p><p></p><p class="bulletIndent1">There is no consensus among experts regarding the optimum type and frequency of testing. Three randomized trials (n = 275 women) that attempted to determine whether testing leads to an improvement in perinatal outcome did not report convincing evidence of improvement or harm but were of low quality [<a href="#rid40">40</a>]. In the largest trial (n = 135 women), women with PPROM were randomly assigned to either a daily NST or a BPP, and neither test had good sensitivity for predicting maternal or fetal infection [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amniotic fluid volume</strong> – Oligohydramnios is associated with an increased risk of umbilical cord compression and shorter latency, but, as with other tests, the value of this finding alone for prediction of adverse fetal/neonatal outcome in PPROM is low [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal growth</strong> – Periodic ultrasound evaluation of fetal growth is reasonable [<a href="#rid7">7</a>] as pathologic processes responsible for PPROM may also interfere with fetal growth [<a href="#rid42">42,43</a>]. As a general rule, growth assessments should be performed no more often than every two to three weeks. (See  <a class="medical medical_review" href="/d/html/6768.html" rel="external">"Fetal growth restriction: Evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Umbilical artery Doppler</strong> – Doppler surveillance is not useful for monitoring fetal status in PPROM, unless growth restriction (FGR) is also present [<a href="#rid44">44-46</a>]. In this setting, the key abnormal umbilical artery Doppler finding would be absent or reversed end-diastolic flow. (See  <a class="medical medical_review" href="/d/html/6768.html" rel="external">"Fetal growth restriction: Evaluation", section on 'Umbilical artery Doppler'</a>.)</p><p></p><p class="headingAnchor" id="H3250063123"><span class="h3">Maternal monitoring</span><span class="headingEndMark"> — </span>Women with PPROM should be monitored for signs of infection; however, there is no consensus as to the best approach. At a minimum, routine clinical parameters (eg, maternal temperature, presence of uterine tenderness, frequency of contractions, maternal and fetal heart rate) should be monitored.</p><p>Periodically monitoring white blood cell counts or other markers for inflammation/infection has not been proven to be useful [<a href="#rid47">47</a>].</p><p>Amniocentesis to obtain amniotic fluid for Gram stain, culture, leukocyte esterase, glucose concentration, and interleukin-6 (IL-6, where available) is more controversial. We do not routinely perform amniocentesis to screen for intra-amniotic infection in asymptomatic women. If the clinical diagnosis of chorioamnionitis is uncertain and we need more information to decide whether to recommend expectant management, then we perform amniocentesis to rule out infection. An in-depth discussion of the diagnosis and management of intraamniotic infection can be found separately. (See  <a class="medical medical_review" href="/d/html/6762.html" rel="external">"Clinical chorioamnionitis"</a>.)</p><p>If there is insufficient amniotic fluid to sample, which occurs in up to 50 percent of patients, then the diagnosis of chorioamnionitis will have to be based on clinical examination and indirect testing such as identification of an abnormal peripheral white blood cell count. The clinical findings, criteria for diagnosis, and treatment of chorioamnionitis are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/6762.html" rel="external">"Clinical chorioamnionitis"</a>.)</p><p class="headingAnchor" id="H2709601992"><span class="h3">Special situations</span></p><p class="headingAnchor" id="H3514084480"><span class="h4">Women with HSV, HIV, or cerclage</span><span class="headingEndMark"> — </span>Expectant management of women with PPROM and genital herpes simplex virus (HSV) or HIV infection is controversial, and opinions about the best course of action diverge widely. These patients are discussed separately. (See  <a class="medical medical_review" href="/d/html/8340.html" rel="external">"Genital herpes simplex virus infection and pregnancy"</a> and  <a class="medical medical_review" href="/d/html/126417.html" rel="external">"Intrapartum and postpartum management of pregnant women with HIV and infant prophylaxis in resource-rich settings", section on 'Preterm premature rupture of membranes'</a>.)</p><p>Expectant management of women with PPROM and a cerclage is also reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/6737.html" rel="external">"Transvaginal cervical cerclage", section on 'Removal of cerclage after PPROM'</a>.)</p><p class="headingAnchor" id="H397788105"><span class="h4">Meconium-stained fluid</span><span class="headingEndMark"> — </span>Patients with PPROM and meconium-stained amniotic fluid should be evaluated for signs of chorioamnionitis. In the absence of these signs, meconium alone is not an indication for intervention.</p><p>Studies of term and preterm PROM patients have generally reported that those with meconium-stained amniotic fluid have higher rates of both overt and subclinical chorioamnionitis and positive amniotic fluid cultures [<a href="#rid48">48-50</a>]. Meconium release predisposes to infection by enhancing the growth of bacteria and lowering phagocytic capacity of neutrophils [<a href="#rid51">51</a>]. However, it is also possible that, in some cases, meconium-like staining is actually pigment associated with decidual hemorrhage (abruption).</p><p class="headingAnchor" id="H428003231"><span class="h4">Twin pregnancy</span><span class="headingEndMark"> — </span>We manage twin pregnancies with PPROM in the same way as singleton pregnancies with PPROM based on clinical experience and generally accepted practice patterns. Some PPROM studies have included both singleton and twin pregnancies, but no studies have specifically evaluated management of twin PPROM except at previable gestational ages [<a href="#rid52">52</a>] or in the setting of delayed-interval delivery. (See  <a class="medical medical_review" href="/d/html/6741.html" rel="external">"Prelabor rupture of membranes before and at the limit of viability"</a> and  <a class="medical medical_review" href="/d/html/6771.html" rel="external">"Multifetal gestation: Approach to delayed-interval delivery"</a>.)</p><p class="headingAnchor" id="H2173837362"><span class="h3">Unproven interventions</span></p><p class="headingAnchor" id="H1855765838"><span class="h4">Supplemental progesterone</span><span class="headingEndMark"> — </span>In a meta-analysis of randomized trials (five trials, 545 participants), initiating <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> supplementation (primarily <a class="drug drug_general" data-topicid="16452" href="/d/drug information/16452.html" rel="external">hydroxyprogesterone caproate</a>) after PPROM did not prolong the latency period or increase the mean gestational age at birth [<a href="#rid53">53</a>]. Hydroxyprogesterone caproate has since been removed from the market because of lack of evidence of efficacy for preventing recurrent preterm birth, which was the approved indication for the medication.</p><p>In patients who were already on supplemental vaginal <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> because of short cervical length, we discontinue the medication upon diagnosis of PPROM. Continuing vaginal administration may increase the risk for ascending infection. </p><p class="headingAnchor" id="H837349811"><span class="h4">Tissue sealants</span><span class="headingEndMark"> — </span>A variety of tissue sealants (eg, fibrin glue, gelatin sponge) have had some success in stopping leakage in case reports. Neither the safety nor the efficacy of these sealants has been established. Tissue sealants are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/6741.html" rel="external">"Prelabor rupture of membranes before and at the limit of viability", section on 'Repair of leaks'</a>.)</p><p class="headingAnchor" id="H3748433300"><span class="h4">Amnioinfusion</span><span class="headingEndMark"> — </span>We recommend against performing antepartum amnioinfusion on patients with PPROM. A 2014 systematic review and meta-analysis compared pregnancy outcome in patients who received antepartum transabdominal amnioinfusion versus those who received usual care for management of PPROM in the third trimester (five randomized trials, n = 241 pregnancies) [<a href="#rid54">54</a>]. Transabdominal amnioinfusion resulted in statistically significant reductions in neonatal death, sepsis/infection, and pulmonary hypoplasia, but data for each outcome were limited to one to two very small trials of low to moderate quality.</p><p>To more fully understand whether amnioinfusion is beneficial in PPROM, more and better information is needed about the effects of specific amnioinfusion protocols, selection of patients (eg, gestational age at rupture of membranes), and other interventions (type, dose, and duration of antibiotics; use of corticosteroids) on perinatal outcome.</p><p class="headingAnchor" id="H1377738766"><span class="h1">TIMING OF DELIVERY</span></p><p class="headingAnchor" id="H1661114308"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Expeditious delivery of women with PPROM is indicated if intrauterine infection, placental abruption, nonreassuring fetal testing, or a high risk of cord prolapse is present or suspected. If the mother and fetus are stable, the pregnancy is ≥34 weeks of gestation, and dating is optimal, we discuss the advantages and disadvantages of delivery versus expectant management with the patient, and we suggest delivery, usually by induction of labor. </p><p>If the pregnancy is suboptimally dated, we continue to manage the pregnancy expectantly until 36 to 37 weeks of gestation (by best estimate), at which time we recommend delivery.</p><p>There are no high-quality data to clearly inform the point at which the potential benefits of ongoing expectant management to achieve a more advanced gestational age at delivery are offset by the potential risks associated with prolonged PPROM: infection, placental abruption, cord prolapse/compression. The optimal time for intervention varies among institutions and depends on the balance between morbidity related to prematurity and morbidity related to complications of PPROM, which can differ in different populations. In our population, we are particularly concerned about morbidity related to complications of prolonged PPROM (eg, chorioamnionitis, antepartum bleeding). </p><p>The American College of Obstetricians and Gynecologists (ACOG) suggests delivery for all patients with PROM ≥37+0 weeks of gestation, either expectant management or immediate delivery for those 34+0 to 36+6 weeks, and expectant management before 34+0 weeks [<a href="#rid7">7</a>]. Although we believe delivery at 34 weeks of gestation is preferable to expectant management in optimally dated pregnancies, some patients may choose expectant management based on the data presented below. Expectant management until term has been advocated by the perinatal group at the University of Sydney [<a href="#rid55">55</a>] and endorsed by the Royal College of Obstetricians and Gynaecologists [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H3225389449"><span class="h2">Comparative trials of timed delivery versus expectant management</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PPROM &lt;37 weeks</strong> – The authors of a 2017 meta-analysis of randomized trials of management of women with PPROM prior to 37 weeks concluded that, in the absence of either fetal or maternal compromise, expectant management until 37 weeks of gestation was preferable to timed early delivery (n = 12 trials, 3617 women, 3628 neonates) [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1">Compared with expectant management until 37 weeks, planned early birth increased the risk of several adverse newborn outcomes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Respiratory distress syndrome (relative risk [RR] 1.26, 95% CI 1.05-1.53)</p><p class="bulletIndent2"><span class="glyph">•</span>Need for mechanical ventilation (RR 1.27, 95% CI 1.02-1.58)</p><p class="bulletIndent2"><span class="glyph">•</span>Admission to the neonatal intensive care unit (RR 1.16, 95% CI 1.08-1.24)</p><p class="bulletIndent2"><span class="glyph">•</span>Neonatal death (RR 2.55, 95% CI 1.17-5.56)</p><p></p><p class="bulletIndent1">It did not reduce the risk of some outcomes of concern, such as neonatal sepsis (RR 0.93, 95% CI 0.66-1.30), positive neonatal blood cultures (RR 1.24, 95% CI 0.70-2.21), overall perinatal mortality (RR 1.76, 95% CI 0.89-3.50), or fetal death (RR 0.45, 95% CI 0.13-1.57).</p><p></p><p class="bulletIndent1">For the mother, planned early birth resulted in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lower rate of chorioamnionitis (RR 0.50, 95% CI 0.26-0.95) </p><p class="bulletIndent2"><span class="glyph">•</span>Shorter total length of hospitalization (mean difference -1.75 days, 95% CI -2.45 to -1.05)</p><p class="bulletIndent2"><span class="glyph">•</span>Higher cesarean delivery rate (RR 1.26, 95% CI 1.11-1.44)</p><p class="bulletIndent2"><span class="glyph">•</span>Higher frequency of endometritis (RR 1.61, 95% CI 1.00-2.59)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PPROM at 34+0 to 36+6 weeks</strong> – A 2018 individual participant data meta-analysis of trials of late PPROM (34+0 to 36+6 weeks) with randomization to immediate delivery or expectant management included three of the trials in the above meta-analysis (n = 2563 women) [<a href="#rid57">57</a>]. Major findings were:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The two approaches resulted in similar rates of the composite adverse neonatal outcome (probable or definitive neonatal sepsis, necrotizing enterocolitis, respiratory distress syndrome, stillbirth, or neonatal death; 9.6 percent with immediate delivery versus 8.3 percent with expectant management; RR 1.20, 95% CI 0.94-1.55).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the mother, immediate delivery reduced the risk of antepartum hemorrhage (1.7 versus 3.0 percent, RR 0.57, 95% CI 0.34-0.95) and chorioamnionitis (1.3 versus 6.4 percent, RR 0.21, 95% CI 0.13-0.35) but modestly increased the risk of cesarean delivery (22 versus 18 percent, RR 1.26, 95% CI 1.08-1.47).</p><p></p><p class="bulletIndent2">The rate of endometritis (0.2 versus 0.6 percent) and the length of hospitalization (3.45 versus 3.39 days) were not statistically different between groups.</p><p></p><p class="bulletIndent1">We have reservations about routine expectant management of PPROM until 37 weeks in all patients, particularly in the United States where we practice. First, the meta-analyses summarized above are dominated by the results of one trial, the Preterm Prelabour Rupture of the Membranes close to Term (PPROMT) trial [<a href="#rid58">58</a>], which contributed almost 50 percent of the patients. Second, the trials in the meta-analyses were conducted over extended periods of time (up to nine years), and major changes occurred in both obstetric and neonatal management during this time period (notably the decreased use of endotracheal intubation and mechanical ventilation in favor of continuous positive airway pressure [CPAP]). Third, there was no uniformity in the way that corticosteroids, tocolytics, and prophylactic antibiotics were administered (given according to local protocols). Fourth, there were significant differences among trials in the interval between PROM and induction of labor in the early delivery groups. Fifth, the trials were conducted in multiple different patient populations, not all of which are similar to patients treated in the United States, and at many different facilities with different levels of resources and different management strategies. Sixth, some of the patients were treated as outpatients, a practice that is not the standard of care in the United States. Finally, and perhaps of greatest importance with respect to practice in the United States, none of the trials addressed the issue of the comparative costs of the two management options.</p><p></p><p class="bulletIndent1">The PPROMEXIL trials accounted for about 30 percent of patients in the meta-analysis. Secondary analysis of these trials found that the rate of early onset neonatal sepsis was increased in GBS-positive pregnancies managed expectantly (15.2 versus 1.8 percent) [<a href="#rid59">59</a>]. The effect of antibiotic prophylaxis on this finding could not be determined. By comparison, the PROMPT trial found similar neonatal sepsis rates in GBS-positive patients managed expectantly and those induced immediately (3.8 versus 3.6 percent) [<a href="#rid58">58</a>]. Maternal antibiotic administration (antepartum and intrapartum) was much more common in PROMPT than PPROMEXIL (92 versus 40 percent). In addition, a 10-year follow-up study of PPROMEXIL reported that expectant management at 34 to 36 weeks did not improve childhood outcomes at 10 to 12 years when compared with induction of labor [<a href="#rid60">60</a>]. These two trials support our recommendations that all patients with PPROM should receive prophylactic antibiotics and, with rare exceptions, they should be delivered when they reach 34 weeks, as described above. (See <a class="local">'Our approach'</a> above and <a class="local">'Administer prophylactic antibiotic therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H2068459021"><span class="h1">DELIVERY</span></p><p class="headingAnchor" id="H1250168434"><span class="h2">Magnesium sulfate for neuroprotection</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">Magnesium sulfate</a> is administered prior to delivery according to standard clinical protocols for fetal neuroprotection (eg, pregnancies at least 24 but &lt;32 weeks of gestation at risk of imminent delivery). (See  <a class="medical medical_review" href="/d/html/4481.html" rel="external">"Neuroprotective effects of in utero exposure to magnesium sulfate"</a>.)</p><p class="headingAnchor" id="H2165276193"><span class="h2">Route of delivery</span><span class="headingEndMark"> — </span>In the absence of contraindications to labor and vaginal birth, most patients will deliver by spontaneous or induced vaginal delivery [<a href="#rid61">61</a>]. Cesarean delivery is performed for standard indications; otherwise, labor is induced.</p><p class="headingAnchor" id="H3623397145"><span class="h2">Cervical ripening</span><span class="headingEndMark"> — </span>Once delivery is indicated, we perform a digital cervical examination to determine whether cervical ripening has occurred naturally. If the cervix is favorable (Bishop score ≥6)  (<a class="graphic graphic_table graphicRef65320" href="/d/graphic/65320.html" rel="external">table 4</a>), <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> is administered for induction according to standard protocols.</p><p>If the cervix is unfavorable, we administer a prostaglandin (<a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>) for cervical ripening; however, the value of a cervical ripening agent in pregnancies with ruptured membranes has not been established. A meta-analysis including 15 randomized trials of misoprostol versus <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> for labor induction in women with term PROM reported the rate of vaginal delivery in 12 and 24 hours was similar for both drugs [<a href="#rid62">62</a>]. Whether misoprostol was advantageous in the subgroup of women with an unfavorable cervix is unknown since this was not evaluated. The optimum dose and route of misoprostol administration have also not been determined. (See  <a class="medical medical_review" href="/d/html/5398.html" rel="external">"Induction of labor: Techniques for preinduction cervical ripening", section on 'Prostaglandin E1 (misoprostol)'</a>.)</p><p>Prostaglandin E2 is a reasonable alternative [<a href="#rid63">63</a>]. There is no evidence that its use increases the risk of infection in women with PROM [<a href="#rid64">64-66</a>]. (See  <a class="medical medical_review" href="/d/html/5398.html" rel="external">"Induction of labor: Techniques for preinduction cervical ripening", section on 'Prostaglandin E2'</a>.)</p><p>We do not use an intracervical balloon catheter for cervical ripening as data suggest that introducing a foreign body probably increases the risk of infection. These data are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/6757.html" rel="external">"Prelabor rupture of membranes at term: Management", section on 'Balloon catheter'</a>.)</p><p class="headingAnchor" id="H3812190148"><span class="h1">MANAGEMENT OF THE NEWBORN</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Maternal risk factors'</a>.)</p><p class="headingAnchor" id="H3413648364"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>The fetus and neonate are at greater risk for PPROM-related morbidity and mortality than the mother  (<a class="graphic graphic_table graphicRef88802" href="/d/graphic/88802.html" rel="external">table 5</a>).</p><p class="headingAnchor" id="H733286094"><span class="h2">Fetal/neonatal</span><span class="headingEndMark"> — </span>For the neonate, morbidity and mortality are primarily related to preterm birth; residual oligohydramnios also plays a role [<a href="#rid67">67</a>]. The type and frequency of prematurity-related morbidity depend on the gestational age at birth and whether chorioamnionitis is present [<a href="#rid68">68</a>]. Fetal exposure to intrauterine inflammation has been associated with an increased risk of neurodevelopmental impairment. (See  <a class="medical medical_review" href="/d/html/4966.html" rel="external">"Preterm birth: Definitions of prematurity, epidemiology, and risk factors for infant mortality"</a> and  <a class="medical medical_review" href="/d/html/4965.html" rel="external">"Overview of short-term complications in preterm infants"</a> and  <a class="medical medical_review" href="/d/html/6762.html" rel="external">"Clinical chorioamnionitis", section on 'Perinatal outcome'</a>.)</p><p>Early, severe, prolonged oligohydramnios can be associated with pulmonary hypoplasia, facial deformation, and orthopedic abnormalities. Such complications are most likely when membrane rupture occurs at less than 23 weeks of gestation. (See  <a class="medical medical_review" href="/d/html/6741.html" rel="external">"Prelabor rupture of membranes before and at the limit of viability", section on 'Pediatric outcomes'</a>.)</p><p class="headingAnchor" id="H1079254756"><span class="h2">Maternal</span><span class="headingEndMark"> — </span>Approximately one-third of women with PPROM develop potentially serious infections, such as chorioamnionitis, endometritis, or septicemia. Endometritis is more common after cesarean than vaginal delivery. The frequency of infection is higher at earlier gestational ages at PPROM [<a href="#rid69">69,70</a>]. (See  <a class="medical medical_review" href="/d/html/6762.html" rel="external">"Clinical chorioamnionitis"</a> and  <a class="medical medical_review" href="/d/html/5488.html" rel="external">"Postpartum endometritis"</a>.)</p><p class="headingAnchor" id="H901951741"><span class="h1">MANAGEMENT OF FUTURE PREGNANCIES</span><span class="headingEndMark"> — </span>As discussed above, a history of PPROM is a strong risk factor for recurrence (see  <a class="medical medical_review" href="/d/html/6754.html" rel="external">"Preterm prelabor rupture of membranes: Clinical manifestations and diagnosis", section on 'Risk factors'</a>). </p><p>PPROM may be related to cervical insufficiency in some cases. In future pregnancies, sonographic measurement of cervical length and placement of a cerclage if cervical length is ≤25 mm before 24 weeks of gestation can reduce the risk of recurrent preterm birth. Daily vaginal <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> administration is an alternative approach for patients with a short cervix. (See  <a class="medical medical_review" href="/d/html/6774.html" rel="external">"Cervical insufficiency", section on 'Ultrasound-based cervical insufficiency'</a> and  <a class="medical medical_review" href="/d/html/450.html" rel="external">"Short cervix before 24 weeks: Screening and management in singleton pregnancies"</a>.)</p><p>Neither screening for asymptomatic infection with treatment of positive results nor empiric antibiotic therapy has been proven to prevent PPROM.</p><p class="bulletIndent1"><span class="glyph">●</span>A single randomized trial evaluated whether screening all pregnant women for genital tract infection (bacterial vaginosis, <em>T. vaginalis</em>, Candidiasis) before 20 weeks plus standard treatment of patients with positive results found that the intervention reduced the number of spontaneous preterm births compared with a control group in which test results were not given to the provider (spontaneous preterm birth 3.0 versus 5.3 percent, 95% CI 1.2-3.6) [<a href="#rid71">71</a>]. Limitations of this trial include that it did not distinguish between preterm births due to preterm labor versus PPROM and the authors only used Gram stain to diagnosis infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2015 systematic review of randomized trials concluded that antibiotic prophylaxis in the second or third trimester did not reduce the risk of PPROM (RR 0.31, 95% CI 0.06-1.49; one trial, 229 women) or preterm birth (RR 0.85, 95% CI 0.64-1.14; five trials, 1480 women); however, the included studies were of low methodological quality [<a href="#rid72">72</a>]. Subsequent trials have also not shown a benefit [<a href="#rid73">73</a>].</p><p></p><p class="headingAnchor" id="H4142052267"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117941.html" rel="external">"Society guideline links: Prelabor rupture of membranes"</a>.)</p><p class="headingAnchor" id="H471488638"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/82972.html" rel="external">"Patient education: Preterm prelabor rupture of membranes (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H984978727"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – The management of women with preterm prelabor rupture of membranes (PPROM) is based upon consideration of several factors, including gestational age, the availability of an appropriate level of neonatal care, the presence or absence of maternal/fetal infection (see <a class="local">'Screen for infection'</a> above), the presence or absence of labor or placental abruption, the stability of the fetal presentation, the fetal heart rate tracing pattern, and cervical status. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients requiring expeditious delivery (unstable patients)</strong> – Expeditious delivery of women with PPROM is indicated if intrauterine infection, placental abruption, nonreassuring fetal testing, or a high risk of cord prolapse is present or suspected. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stable patients &lt;34 weeks</strong> – For stable patients (mother and fetus) with PPROM &lt;34 weeks, we suggest expectant management rather than delivery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'Components of expectant management'</a> above and <a class="local">'Our approach'</a> above). In addition:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend administering a course of antenatal corticosteroids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). Antenatal corticosteroids reduce the morbidity and mortality of prematurity if preterm delivery occurs. (See <a class="local">'Administer antenatal corticosteroids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend administering a course of prophylactic antibiotics (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). Our preference is <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> 2 grams intravenously every 6 hours for 48 hours, followed by <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> 875 mg orally twice daily for an additional five days. In addition, we administer one dose of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> 1 gram orally at the time of admission. (See <a class="local">'Administer prophylactic antibiotic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We hospitalize women during the entire period of expectant management (diagnosis of PPROM to delivery). (See <a class="local">'Hospitalization versus home care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stable patients ≥34 weeks</strong> – For stable patients (mother and fetus) with optimally dated pregnancies at ≥34 weeks, we suggest delivery rather than expectant management (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If gestational dating is suboptimal, we suggest expectant management with delivery when our best estimate of gestational age is 36 to 37 weeks (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Our approach'</a> above and <a class="local">'Comparative trials of timed delivery versus expectant management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – The fetus and neonate are at greater risk for PPROM-related morbidity and mortality than the mother  (<a class="graphic graphic_table graphicRef88802" href="/d/graphic/88802.html" rel="external">table 5</a>). (See <a class="local">'Outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Future pregnancy</strong> – A history of PPROM is a strong risk factor for recurrence. Monitoring cervical length in future pregnancies and treating patients with a short cervix with vaginal <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> or cerclage may improve pregnancy outcome. Neither screening for asymptomatic infection with treatment of positive results nor empiric antibiotic therapy has been proven to prevent PPROM. (See <a class="local">'Management of future pregnancies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lorthe E, Ancel PY, Torchin H, et al. Impact of Latency Duration on the Prognosis of Preterm Infants after Preterm Premature Rupture of Membranes at 24 to 32 Weeks' Gestation: A National Population-Based Cohort Study. J Pediatr 2017; 182:47.</a></li><li><a class="nounderline abstract_t">Manuck TA, Maclean CC, Silver RM, Varner MW. Preterm premature rupture of membranes: does the duration of latency influence perinatal outcomes? Am J Obstet Gynecol 2009; 201:414.e1.</a></li><li><a class="nounderline abstract_t">Frenette P, Dodds L, Armson BA, Jangaard K. Preterm prelabour rupture of membranes: effect of latency on neonatal and maternal outcomes. J Obstet Gynaecol Can 2013; 35:710.</a></li><li><a class="nounderline abstract_t">Roos C, Schuit E, Scheepers HC, et al. Predictive Factors for Delivery within 7 Days after Successful 48-Hour Treatment of Threatened Preterm Labor. AJP Rep 2015; 5:e141.</a></li><li><a class="nounderline abstract_t">Park CK, Isayama T, McDonald SD. Antenatal Corticosteroid Therapy Before 24 Weeks of Gestation: A Systematic Review and Meta-analysis. Obstet Gynecol 2016; 127:715.</a></li><li><a class="nounderline abstract_t">Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017; 3:CD004454.</a></li><li><a class="nounderline abstract_t">Prelabor Rupture of Membranes: ACOG Practice Bulletin, Number 217. Obstet Gynecol 2020; 135:e80. Reaffirmed 2023.</a></li><li><a class="nounderline abstract_t">Committee on Obstetric Practice. Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation. Obstet Gynecol 2017; 130:e102.</a></li><li><a class="nounderline abstract_t">Walters A, McKinlay C, Middleton P, et al. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Syst Rev 2022; 4:CD003935.</a></li><li><a class="nounderline abstract_t">Shimokaze T, Akaba K, Banzai M, et al. Premature rupture of membranes and neonatal respiratory morbidity at 32-41 weeks' gestation: a retrospective single-center cohort study. J Obstet Gynaecol Res 2015; 41:1193.</a></li><li><a class="nounderline abstract_t">Kunzmann S, Collins JJ, Kuypers E, Kramer BW. Thrown off balance: the effect of antenatal inflammation on the developing lung and immune system. Am J Obstet Gynecol 2013; 208:429.</a></li><li><a class="nounderline abstract_t">Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996; 97:210.</a></li><li><a class="nounderline abstract_t">Hartling L, Liang Y, Lacaze-Masmonteil T. Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2012; 97:F8.</a></li><li><a class="nounderline abstract_t">Porreco R, Garite TJ, Combs CA, et al. Booster course of antenatal corticosteroids after preterm prelabor rupture of membranes: a double-blind randomized trial. Am J Obstet Gynecol MFM 2023; 5:100896.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Core La BQ, Mastrobattista JM, Bishop K, Newton ER. Gram-stain diagnosis of bacterial vaginosis after rupture of membranes. Am J Perinatol 2000; 17:315.</a></li><li><a class="nounderline abstract_t">Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.</a></li><li><a class="nounderline abstract_t">Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 2013; :CD001058.</a></li><li><a class="nounderline abstract_t">Lee J, Romero R, Kim SM, et al. A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM. J Matern Fetal Neonatal Med 2016; 29:2727.</a></li><li><a class="nounderline abstract_t">Kacerovsky M, Romero R, Stepan M, et al. Antibiotic administration reduces the rate of intraamniotic inflammation in preterm prelabor rupture of the membranes. Am J Obstet Gynecol 2020; 223:P114.E1.</a></li><li><a class="nounderline abstract_t">Chatzakis C, Papatheodorou S, Sarafidis K, et al. Effect on perinatal outcome of prophylactic antibiotics in preterm prelabor rupture of membranes: network meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol 2020; 55:20.</a></li><li><a class="nounderline abstract_t">Mercer BM, Miodovnik M, Thurnau GR, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 1997; 278:989.</a></li><li><a class="nounderline abstract_t">Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery. Obstet Gynecol 2018; 132:e103.</a></li><li><a class="nounderline abstract_t">Seaman RD, Kopkin RH, Turrentine MA. Erythromycin vs azithromycin for treatment of preterm prelabor rupture of membranes: a systematic review and meta-analysis. Am J Obstet Gynecol 2022; 226:794.</a></li><li><a class="nounderline abstract_t">Grigsby PL, Novy MJ, Sadowsky DW, et al. Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. Am J Obstet Gynecol 2012; 207:475.e1.</a></li><li><a class="nounderline abstract_t">Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial. Lancet 2008; 372:1310.</a></li><li><a class="nounderline abstract_t">Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet 2008; 372:1319.</a></li><li><a class="nounderline abstract_t">Wolf MF, Miron D, Peleg D, et al. Reconsidering the Current Preterm Premature Rupture of Membranes Antibiotic Prophylactic Protocol. Am J Perinatol 2015; 32:1247.</a></li><li><a class="nounderline abstract_t">Yoon BH, Romero R, Park JY, et al. Antibiotic administration can eradicate intra-amniotic infection or intra-amniotic inflammation in a subset of patients with preterm labor and intact membranes. Am J Obstet Gynecol 2019; 221:142.e1.</a></li><li><a class="nounderline abstract_t">Lorthe E, Letouzey M, Torchin H, et al. Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort. BJOG 2022; 129:1560.</a></li><li><a class="nounderline abstract_t">Mackeen AD, Seibel-Seamon J, Muhammad J, et al. Tocolytics for preterm premature rupture of membranes. Cochrane Database Syst Rev 2014; :CD007062.</a></li><li><a class="nounderline abstract_t">Carlan SJ, O'Brien WF, Parsons MT, Lense JJ. Preterm premature rupture of membranes: a randomized study of home versus hospital management. Obstet Gynecol 1993; 81:61.</a></li><li><a class="nounderline abstract_t">Turnbull DA, Wilkinson C, Gerard K, et al. Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women. Lancet 2004; 363:1104.</a></li><li><a class="nounderline abstract_t">Abou El Senoun G, Dowswell T, Mousa HA. Planned home versus hospital care for preterm prelabour rupture of the membranes (PPROM) prior to 37 weeks' gestation. Cochrane Database Syst Rev 2014; :CD008053.</a></li><li><a class="nounderline abstract_t">Petit C, Deruelle P, Behal H, et al. Preterm premature rupture of membranes: Which criteria contraindicate home care management? Acta Obstet Gynecol Scand 2018; 97:1499.</a></li><li><a class="nounderline abstract_t">Point F, Ghesquiere L, Drumez E, et al. Risk factors associated with shortened latency before delivery in outpatients managed for preterm prelabor rupture of membranes. Acta Obstet Gynecol Scand 2022; 101:119.</a></li><li><a class="nounderline abstract_t">Lewis DF, Robichaux AG, Jaekle RK, et al. Expectant management of preterm premature rupture of membranes and nonvertex presentation: what are the risks? Am J Obstet Gynecol 2007; 196:566.e1.</a></li><li><a class="nounderline abstract_t">Hanley ML, Vintzileos AM. Biophysical testing in premature rupture of the membranes. Semin Perinatol 1996; 20:418.</a></li><li><a class="nounderline abstract_t">Lewis DF, Adair CD, Weeks JW, et al. A randomized clinical trial of daily nonstress testing versus biophysical profile in the management of preterm premature rupture of membranes. Am J Obstet Gynecol 1999; 181:1495.</a></li><li><a class="nounderline abstract_t">Sharp GC, Stock SJ, Norman JE. Fetal assessment methods for improving neonatal and maternal outcomes in preterm prelabour rupture of membranes. Cochrane Database Syst Rev 2014; :CD010209.</a></li><li><a class="nounderline abstract_t">Mercer BM, Rabello YA, Thurnau GR, et al. The NICHD-MFMU antibiotic treatment of preterm PROM study: impact of initial amniotic fluid volume on pregnancy outcome. Am J Obstet Gynecol 2006; 194:438.</a></li><li><a class="nounderline abstract_t">Bukowski R, Gahn D, Denning J, Saade G. Impairment of growth in fetuses destined to deliver preterm. Am J Obstet Gynecol 2001; 185:463.</a></li><li><a class="nounderline abstract_t">Deering SH, Patel N, Spong CY, et al. Fetal growth after preterm premature rupture of membranes: is it related to amniotic fluid volume? J Matern Fetal Neonatal Med 2007; 20:397.</a></li><li><a class="nounderline abstract_t">Leo MV, Skurnick JH, Ganesh VV, et al. Clinical chorioamnionitis is not predicted by umbilical artery Doppler velocimetry in patients with premature rupture of membranes. Obstet Gynecol 1992; 79:916.</a></li><li><a class="nounderline abstract_t">Abramowicz JS, Sherer DM, Warsof SL, Levy DL. Fetoplacental and uteroplacental Doppler blood flow velocity analysis in premature rupture of membranes. Am J Perinatol 1992; 9:353.</a></li><li><a class="nounderline abstract_t">Carroll SG, Papaioannou S, Nicolaides KH. Doppler studies of the placental and fetal circulation in pregnancies with preterm prelabor amniorrhexis. Ultrasound Obstet Gynecol 1995; 5:184.</a></li><li><a class="nounderline abstract_t">Tita AT, Andrews WW. Diagnosis and management of clinical chorioamnionitis. Clin Perinatol 2010; 37:339.</a></li><li><a class="nounderline abstract_t">Romero R, Hanaoka S, Mazor M, et al. Meconium-stained amniotic fluid: a risk factor for microbial invasion of the amniotic cavity. Am J Obstet Gynecol 1991; 164:859.</a></li><li><a class="nounderline abstract_t">Duff P. Premature rupture of the membranes in term patients. Semin Perinatol 1996; 20:401.</a></li><li><a class="nounderline abstract_t">Seaward PG, Hannah ME, Myhr TL, et al. International Multicentre Term Prelabor Rupture of Membranes Study: evaluation of predictors of clinical chorioamnionitis and postpartum fever in patients with prelabor rupture of membranes at term. Am J Obstet Gynecol 1997; 177:1024.</a></li><li><a class="nounderline abstract_t">Clark P, Duff P. Inhibition of neutrophil oxidative burst and phagocytosis by meconium. Am J Obstet Gynecol 1995; 173:1301.</a></li><li><a class="nounderline abstract_t">Myrick O, Dotters-Katz S, Grace M, et al. Prophylactic Antibiotics in Twin Pregnancies Complicated by Previable Preterm Premature Rupture of Membranes. AJP Rep 2016; 6:e277.</a></li><li><a class="nounderline abstract_t">Quist-Nelson J, Parker P, Mokhtari N, et al. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol 2018; 219:346.</a></li><li><a class="nounderline abstract_t">Hofmeyr GJ, Eke AC, Lawrie TA. Amnioinfusion for third trimester preterm premature rupture of membranes. Cochrane Database Syst Rev 2014; :CD000942.</a></li><li><a class="nounderline abstract_t">Bond DM, Middleton P, Levett KM, et al. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. Cochrane Database Syst Rev 2017; 3:CD004735.</a></li><li><a class="nounderline abstract_t">Thomson AJ, Royal College of Obstetricians and Gynaecologists. Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes from 24+0 Weeks of Gestation: Green-top Guideline No. 73. BJOG 2019; 126:e152.</a></li><li><a class="nounderline abstract_t">Quist-Nelson J, de Ruigh AA, Seidler AL, et al. Immediate Delivery Compared With Expectant Management in Late Preterm Prelabor Rupture of Membranes: An Individual Participant Data Meta-analysis. Obstet Gynecol 2018; 131:269.</a></li><li><a class="nounderline abstract_t">Morris JM, Roberts CL, Bowen JR, et al. Immediate delivery compared with expectant management after preterm pre-labour rupture of the membranes close to term (PPROMT trial): a randomised controlled trial. Lancet 2016; 387:444.</a></li><li><a class="nounderline abstract_t">Tajik P, van der Ham DP, Zafarmand MH, et al. Using vaginal Group B Streptococcus colonisation in women with preterm premature rupture of membranes to guide the decision for immediate delivery: a secondary analysis of the PPROMEXIL trials. BJOG 2014; 121:1263.</a></li><li><a class="nounderline abstract_t">Simons NE, de Ruigh AA, van 't Hooft J, et al. Childhood outcomes after induction of labor or expectant management for preterm prelabor rupture of membranes: a 10-year follow-up of the PPROMEXIL trials. Am J Obstet Gynecol 2023; 228:588.e1.</a></li><li><a class="nounderline abstract_t">Kunze M, Hart JE, Lynch AM, Gibbs RS. Intrapartum management of premature rupture of membranes: effect on cesarean delivery rate. Obstet Gynecol 2011; 118:1247.</a></li><li><a class="nounderline abstract_t">Lin MG, Nuthalapaty FS, Carver AR, et al. Misoprostol for labor induction in women with term premature rupture of membranes: a meta-analysis. Obstet Gynecol 2005; 106:593.</a></li><li><a class="nounderline abstract_t">ACOG Committee on Practice Bulletins -- Obstetrics. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol 2009; 114:386. Reaffirmed 2020.</a></li><li><a class="nounderline abstract_t">Ray DA, Garite TJ. Prostaglandin E2 for induction of labor in patients with premature rupture of membranes at term. Am J Obstet Gynecol 1992; 166:836.</a></li><li><a class="nounderline abstract_t">Hannah ME, Ohlsson A, Farine D, et al. Induction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group. N Engl J Med 1996; 334:1005.</a></li><li><a class="nounderline abstract_t">Zhang Y, Wang J, Yu Y, et al. Misoprostol versus prostaglandin E2 gel for labor induction in premature rupture of membranes after 34 weeks of pregnancy. Int J Gynaecol Obstet 2015; 130:214.</a></li><li><a class="nounderline abstract_t">Pergialiotis V, Bellos I, Fanaki M, et al. The impact of residual oligohydramnios following preterm premature rupture of membranes on adverse pregnancy outcomes: a meta-analysis. Am J Obstet Gynecol 2020; 222:628.</a></li><li><a class="nounderline abstract_t">Soraisham AS, Singhal N, McMillan DD, et al. A multicenter study on the clinical outcome of chorioamnionitis in preterm infants. Am J Obstet Gynecol 2009; 200:372.e1.</a></li><li><a class="nounderline abstract_t">Beydoun SN, Yasin SY. Premature rupture of the membranes before 28 weeks: conservative management. Am J Obstet Gynecol 1986; 155:471.</a></li><li><a class="nounderline abstract_t">Garite TJ, Freeman RK. Chorioamnionitis in the preterm gestation. Obstet Gynecol 1982; 59:539.</a></li><li><a class="nounderline abstract_t">Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ 2004; 329:371.</a></li><li><a class="nounderline abstract_t">Thinkhamrop J, Hofmeyr GJ, Adetoro O, et al. Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity. Cochrane Database Syst Rev 2015; 1:CD002250.</a></li><li><a class="nounderline abstract_t">Bellad MB, Hoffman MK, Mallapur AA, et al. Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo-controlled clinical trial. BJOG 2018; 125:1601.</a></li></ol></div><div id="topicVersionRevision">Topic 120959 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28081890" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Impact of Latency Duration on the Prognosis of Preterm Infants after Preterm Premature Rupture of Membranes at 24 to 32 Weeks' Gestation: A National Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19788972" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Preterm premature rupture of membranes: does the duration of latency influence perinatal outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24007706" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Preterm prelabour rupture of membranes: effect of latency on neonatal and maternal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26495173" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Predictive Factors for Delivery within 7 Days after Successful 48-Hour Treatment of Threatened Preterm Labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26959200" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antenatal Corticosteroid Therapy Before 24 Weeks of Gestation: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28321847" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32080050" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prelabor Rupture of Membranes: ACOG Practice Bulletin, Number 217.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28742678" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35377461" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832468" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Premature rupture of membranes and neonatal respiratory morbidity at 32-41 weeks' gestation: a retrospective single-center cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23313727" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Thrown off balance: the effect of antenatal inflammation on the developing lung and immune system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8584379" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21697236" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36796641" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Booster course of antenatal corticosteroids after preterm prelabor rupture of membranes: a double-blind randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11144314" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Gram-stain diagnosis of bacterial vaginosis after rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21088663" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297389" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antibiotics for preterm rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26441216" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Antibiotic administration reduces the rate of intraamniotic inflammation in preterm prelabor rupture of the membranes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31633844" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect on perinatal outcome of prophylactic antibiotics in preterm prelabor rupture of membranes: network meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9307346" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30134425" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34973176" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Erythromycin vs azithromycin for treatment of preterm prelabor rupture of membranes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23111115" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18804274" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18804276" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26023907" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Reconsidering the Current Preterm Premature Rupture of Membranes Antibiotic Prophylactic Protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30928566" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antibiotic administration can eradicate intra-amniotic infection or intra-amniotic inflammation in a subset of patients with preterm labor and intact membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34954867" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24578236" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tocolytics for preterm premature rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416463" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Preterm premature rupture of membranes: a randomized study of home versus hospital management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15064028" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24729384" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Planned home versus hospital care for preterm prelabour rupture of the membranes (PPROM) prior to 37 weeks' gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30080248" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Preterm premature rupture of membranes: Which criteria contraindicate home care management?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34747005" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risk factors associated with shortened latency before delivery in outpatients managed for preterm prelabor rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17547897" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Expectant management of preterm premature rupture of membranes and nonvertex presentation: what are the risks?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8912996" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Biophysical testing in premature rupture of the membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601934" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A randomized clinical trial of daily nonstress testing versus biophysical profile in the management of preterm premature rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25279580" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fetal assessment methods for improving neonatal and maternal outcomes in preterm prelabour rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16458643" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The NICHD-MFMU antibiotic treatment of preterm PROM study: impact of initial amniotic fluid volume on pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11518910" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Impairment of growth in fetuses destined to deliver preterm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17674244" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fetal growth after preterm premature rupture of membranes: is it related to amniotic fluid volume?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1579313" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical chorioamnionitis is not predicted by umbilical artery Doppler velocimetry in patients with premature rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1418132" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Fetoplacental and uteroplacental Doppler blood flow velocity analysis in premature rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7788493" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Doppler studies of the placental and fetal circulation in pregnancies with preterm prelabor amniorrhexis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20569811" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Diagnosis and management of clinical chorioamnionitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1900664" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Meconium-stained amniotic fluid: a risk factor for microbial invasion of the amniotic cavity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8912994" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Premature rupture of the membranes in term patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9396886" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : International Multicentre Term Prelabor Rupture of Membranes Study: evaluation of predictors of clinical chorioamnionitis and postpartum fever in patients with prelabor rupture of membranes at term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7485342" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Inhibition of neutrophil oxidative burst and phagocytosis by meconium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27551580" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prophylactic Antibiotics in Twin Pregnancies Complicated by Previable Preterm Premature Rupture of Membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29614278" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24683009" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Amnioinfusion for third trimester preterm premature rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28257562" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31207667" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes from 24+0 Weeks of Gestation: Green-top Guideline No. 73.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29324621" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Immediate Delivery Compared With Expectant Management in Late Preterm Prelabor Rupture of Membranes: An Individual Participant Data Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26564381" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Immediate delivery compared with expectant management after preterm pre-labour rupture of the membranes close to term (PPROMT trial): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24862166" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Using vaginal Group B Streptococcus colonisation in women with preterm premature rupture of membranes to guide the decision for immediate delivery: a secondary analysis of the PPROMEXIL trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36787813" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Childhood outcomes after induction of labor or expectant management for preterm prelabor rupture of membranes: a 10-year follow-up of the PPROMEXIL trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22105253" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Intrapartum management of premature rupture of membranes: effect on cesarean delivery rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135593" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Misoprostol for labor induction in women with term premature rupture of membranes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19623003" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : ACOG Practice Bulletin No. 107: Induction of labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1550149" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prostaglandin E2 for induction of labor in patients with premature rupture of membranes at term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8598837" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Induction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26118328" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Misoprostol versus prostaglandin E2 gel for labor induction in premature rupture of membranes after 34 weeks of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109463" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The impact of residual oligohydramnios following preterm premature rupture of membranes on adverse pregnancy outcomes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19217596" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A multicenter study on the clinical outcome of chorioamnionitis in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3752169" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Premature rupture of the membranes before 28 weeks: conservative management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7070724" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Chorioamnionitis in the preterm gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15294856" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25621770" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29790266" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo-controlled clinical trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
